Increased expression levels of the pvcrt-o and pvmdr1 genes in a patient with severe Plasmodium vivax malaria

Malar J. 2009 Apr 2:8:55. doi: 10.1186/1475-2875-8-55.

Abstract

Background: There are increasing reports of severe clinical cases exclusively associated with Plasmodium vivax infections. Notably, this severity has been recently suggested to be associated with chloroquine resistance.

Patients: Two different patients presented at the Hospital Clinic in Barcelona with P. vivax malaria episodes. One patient had severe symptoms and the other mild symptoms. Both patients traveled through the Brazilian Amazon (Manaus) in 2007. For both patients the current diagnosis of malaria was the first. Two other patients with mild symptoms presented to the "Centro de Pesquisa em Medicina Tropical", also in the Brazilian Amazon (Rondônia) in 2000.

Methods: To exclude the possibility that the patient's severe symptoms were due to Plasmodium falciparum, a nested PCR was performed. A magnetic method was used to purify P. vivax free of human leukocytes. Quantitative real-time PCR was performed to compare the transcript levels of two main transporters likely to be involved in chloroquine resistance in P. vivax, namely the P. vivax chloroquine resistance transporter, pvcrt-o, and the P. vivax multidrug resistance transporter, pvmdr 1.

Results: Results demonstrated that the severe clinical symptoms were exclusively due to P. vivax. The patient presented acute respiratory conditions requiring admission to the intensive care unit. The magnetic method showed highly purified infected-reticulocytes with mature stages. In addition, it was found that parasites obtained from the severe patient had up to 2.9-fold increase in pvmdr1 levels and up to 21.9-fold increase in pvcrt-o levels compared to expression levels of parasites from the other patients with mild symptoms.

Conclusion: This is the first clinical case of severe disease exclusively associated with vivax malaria in Spain. Moreover, these findings suggest that clinical severity could be associated with increased expression levels of parasite genes likely involved in chloroquine resistance. It is necessary to further explore the potential of pvmdr1 and particularly pvcrt-o expression levels as molecular markers of severe disease in P. vivax.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Animals
  • Antimalarials / pharmacology
  • Antimalarials / therapeutic use
  • Chloroquine / pharmacology
  • Chloroquine / therapeutic use
  • Drug Resistance, Multiple / genetics*
  • Erythrocytes / parasitology
  • Gene Expression
  • Genes, Protozoan
  • Humans
  • Leukocytes / parasitology
  • Magnetics / instrumentation
  • Malaria, Vivax / drug therapy
  • Malaria, Vivax / genetics*
  • Malaria, Vivax / parasitology
  • Malaria, Vivax / pathology
  • Male
  • Membrane Transport Proteins / metabolism*
  • Multidrug Resistance-Associated Proteins / metabolism*
  • Plasmodium vivax / drug effects
  • Plasmodium vivax / genetics*
  • Plasmodium vivax / isolation & purification
  • Polymerase Chain Reaction
  • Promoter Regions, Genetic
  • Protozoan Proteins / metabolism*
  • Severity of Illness Index
  • Spain

Substances

  • Antimalarials
  • Crt-o protein, Plasmodium vivax
  • Mdr1 protein, Plasmodium vivax
  • Membrane Transport Proteins
  • Multidrug Resistance-Associated Proteins
  • Protozoan Proteins
  • Chloroquine